NCT02777749View on ClinicalTrials.gov

Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

July 19, 2016

Primary Completion Date

September 19, 2017

Study Completion Date

November 1, 2017

Conditions
Osteoarthritis
Interventions
DRUG

Bupivacaine

15 cc's of 0.5% bupivacaine or 50 cc's of 0.25% short-acting bupivacaine (SB), intramuscular injection

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
lead

Columbia University

OTHER

NCT02777749 - Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter